Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited has reported an on-market buy-back, confirming the purchase of 5,419 ordinary fully paid shares. The latest notification, dated April 9, 2024, is part of the company’s ongoing share buy-back program, aimed at reducing outstanding stock and potentially enhancing shareholder value.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
